Making headway: Bioven’s contract research partners include the Beatson Cancer Institute in Glasgow, Scotland, Pangea Biotech in Catalan, Spain and International Medical University (IMU) in Malaysia (pictured, research scientist Sylvia Gan at IMU). Photos: AZMAN GHANI/The Star
Big pharma's contingency for expiring patents: How top global pharmaceutical firms are reinventing themselves to cope with major upcoming challenges
For years, big pharma has braced itself for an impending patent cliff – when patents expire, so does market exclusivity and resulting in an abrupt drop in sales. And with few new “blockbusters” – drugs with annual sales of more than US$1bil (RM3.56bil) each – in the pipeline, it is no wonder the industry has been scrambling to reinvent itself.
Subscribe or renew your subscriptions to win prizes worth up to RM68,000!
